Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories reported strong top-line growth for the quarter ended June 30, 2026. Net sales were $12.593 billion, up 13.0% year over year, with comparable sales growth of 4.8%. GAAP diluted EPS was $0.53 versus $1.01 a year ago, while adjusted diluted EPS, which excludes $1.362 billion of specified after-tax charges including $658 million of intangible amortization and acquisition- and legal-related costs, rose to $1.31 from $1.26.
Diagnostics and Medical Devices led performance, with comparable sales growth of 2.9% and 8.4% respectively, while Established Pharmaceuticals grew 8.7% and Nutrition declined 3.6% on a comparable basis. Abbott completed the acquisition of Exact Sciences, advancing its Cancer Diagnostics business, and highlighted progress in key pipeline programs, including completion of enrollment in the TECTONIC trial, CE Mark for the Libre Duo glucose‑ketone sensor, and FDA submission for the Amulet 360 device.
Management reaffirmed full‑year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full‑year adjusted EPS guidance to $5.45–$5.60, with third‑quarter adjusted EPS projected at $1.38–$1.46. The company returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.
ABBOTT LABORATORIES director John G. Stratton reported a compensation-related grant of stock-based units, not an open-market trade. On the reported date, he acquired 432 stock equivalent units tied to Abbott common shares at a reference value of $90.74 per unit. These units represent director fees credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash around age 65 or upon retirement from the board.
The stock equivalent units earn the same return as if the fees were invested in Abbott shares and the reported balance also reflects units accumulated through a dividend reinvestment feature. Following this grant, Stratton’s account holds a total of 14,022 stock equivalent units.
Roman Michael F reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 416 stock equivalent units as compensation. These units were credited on 2026-06-30 at a reference price of $90.74 per unit and are tied to director fees.
The stock equivalent units track the return Abbott shares would have earned, but are paid out in cash, generally at age 65 or when the director retires from the board. After this award, Roman holds a total of 6,746 stock equivalent units, including amounts accumulated through a dividend reinvestment feature.
Abbott Laboratories director Patricia Paola Gonzalez received a compensation-related grant of derivative securities. She acquired 363 Stock Equivalent Units on Common Shares at a reference value of $90.74 per unit, increasing her directly held stock equivalent unit balance to 5,963 units. These units are credited as director fees into a stock equivalent unit account under a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board, earning the same return as if invested in Abbott shares.
Abbott Laboratories director Kevin T. Conroy reported a compensation-related award of stock equivalent units. On this Form 4, he acquired 231 stock equivalent units at a reference price of $90.74 per unit, bringing his total reported holdings of this derivative instrument to 231 units.
The award represents director fees credited to a stock equivalent unit account under a grantor trust established by the director. These units track Abbott common share performance and are paid in cash, generally at age 65 or upon retirement from the board, rather than involving open-market share purchases or sales.
Abbott Laboratories director Nita Ahuja received a grant of 347 stock equivalent units on Common Shares as director compensation. These units, valued using a reference price of $90.74 per unit, increased her stock equivalent unit balance to 450 units. Director fees are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. The units earn the same return as if the fees were invested in Abbott shares, and the balance also includes units acquired through a dividend reinvestment feature.
Abbott Laboratories executive vice president Louis H. Morrone reported a routine tax-withholding transaction in company stock. On the reported date, 269 common shares were withheld at $92.71 per share to cover tax obligations, leaving him with 76,574 common shares held directly. He also has an indirect holding of 12 common shares through a profit sharing trust, reflecting the balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2026.
Abbott Laboratories executive Elizabeth C. Cushman reported a routine tax-related share disposition. On this Form 4, she surrendered 560 common shares at a value of $94.12 per share to cover tax obligations.
After this tax-withholding disposition, she directly holds 38,013 Abbott common shares, so the transaction represents a small portion of her overall reported holdings and does not reflect an open-market sale.
Abbott Laboratories director John G. Stratton reported an open-market purchase of 2,000 common shares on May 7, 2026 at a price of $86.82 per share. Following this transaction, he directly owns 23,319 common shares of Abbott Laboratories.
ABT filing under Rule 144 discloses a proposed sale of 7,587 shares of Common Stock listed as "RSUs Paid In Shares" with an execution date of 04/24/2026 and a broker of record of Janney Montgomery Scott LLC. The filing also records that 29,211 shares of Common Stock were sold on 04/27/2026 by Robert J. Alpern, with a separate numeric line showing 2,703,457 (contextual ownership or position figure as listed).